KR20180102674A - 암 질환의 단계 구분, 유형 분류 및 치료를 위한 수단 및 방법 - Google Patents

암 질환의 단계 구분, 유형 분류 및 치료를 위한 수단 및 방법 Download PDF

Info

Publication number
KR20180102674A
KR20180102674A KR1020187024606A KR20187024606A KR20180102674A KR 20180102674 A KR20180102674 A KR 20180102674A KR 1020187024606 A KR1020187024606 A KR 1020187024606A KR 20187024606 A KR20187024606 A KR 20187024606A KR 20180102674 A KR20180102674 A KR 20180102674A
Authority
KR
South Korea
Prior art keywords
cancer
dcc
cells
somatic
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020187024606A
Other languages
English (en)
Korean (ko)
Inventor
크리스토프 클라인
세바스찬 슈아이틀러
멜라니 베르너-클라인
마르틴 호프만
이사벨 호다크
Original Assignee
프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우
우니퍼지태트 레겐스부르크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우, 우니퍼지태트 레겐스부르크 filed Critical 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우
Publication of KR20180102674A publication Critical patent/KR20180102674A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020187024606A 2016-01-27 2017-01-27 암 질환의 단계 구분, 유형 분류 및 치료를 위한 수단 및 방법 Pending KR20180102674A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease
EP16152883.1 2016-01-27
PCT/EP2017/051789 WO2017129753A1 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (1)

Publication Number Publication Date
KR20180102674A true KR20180102674A (ko) 2018-09-17

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187024606A Pending KR20180102674A (ko) 2016-01-27 2017-01-27 암 질환의 단계 구분, 유형 분류 및 치료를 위한 수단 및 방법

Country Status (10)

Country Link
US (1) US11702701B2 (enExample)
EP (2) EP3199641B1 (enExample)
JP (1) JP2019508032A (enExample)
KR (1) KR20180102674A (enExample)
CN (1) CN108770360B (enExample)
AU (1) AU2017211976B2 (enExample)
CA (1) CA3012404A1 (enExample)
ES (1) ES2905208T3 (enExample)
SG (1) SG11201805990XA (enExample)
WO (1) WO2017129753A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673541B1 (en) 1998-09-18 2004-01-06 Micromet Ag DNA amplification of a single cell
WO2002037113A2 (en) * 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
ITRM20110149A1 (it) * 2011-03-25 2012-09-26 Massimo Zollo Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione.
WO2013009632A2 (en) * 2011-07-08 2013-01-17 The University Of Utah Research Foundation Methods of detecting hereditary cancer predisposition
EP3211099A1 (en) * 2011-12-10 2017-08-30 Abbott Molecular Inc. Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma
WO2015023551A1 (en) * 2013-08-13 2015-02-19 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
US10273538B2 (en) 2014-02-05 2019-04-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Error-free sequencing of DNA

Also Published As

Publication number Publication date
AU2017211976B2 (en) 2022-09-22
US11702701B2 (en) 2023-07-18
JP2019508032A (ja) 2019-03-28
AU2017211976A1 (en) 2018-08-02
CN108770360A (zh) 2018-11-06
EP3199641B1 (en) 2021-09-29
CN108770360B (zh) 2022-06-14
WO2017129753A8 (en) 2017-10-19
EP3199641A1 (en) 2017-08-02
WO2017129753A1 (en) 2017-08-03
ES2905208T3 (es) 2022-04-07
SG11201805990XA (en) 2018-08-30
CA3012404A1 (en) 2017-08-03
US20190062845A1 (en) 2019-02-28
EP3408411A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
KR102149483B1 (ko) 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
TW201632629A (zh) 用於癌症診斷與預後的方法
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
AU2016381174A1 (en) Methods for reducing Ataxin-2 expression
KR20220160053A (ko) 다발성 골수종에서의 면역요법 표적 및 그의 식별 방법
CN109476698A (zh) 基于基因的炎性肠病诊断
KR20180049093A (ko) 신규한 바이오마커 및 암의 치료 방법
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN111405901B (zh) 含有miRNA的癌症治疗用医药组合物
CN101631876A (zh) 2型糖尿病的遗传易感性变体
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
CN116867908A (zh) 端粒的物理表征
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
CN108624683B (zh) Usp48基因突变在acth型垂体腺瘤分子诊断中的应用
CN115362255A (zh) 用无七之子2(sos2)抑制剂治疗眼科疾患
AU2017211976B2 (en) Means and methods for staging, typing and treating a cancerous disease
KR20220118096A (ko) 항암제에 대한 내성 진단용 조성물
US20040138441A1 (en) Novel gene functionally related to dyslexia
KR102647919B1 (ko) App 돌연변이 세포 및 이의 이용
CN111556894A (zh) 用于调控gsk3b表达的寡核苷酸
US20030219787A1 (en) Novel human gene functionally related to dyslexia
KR20230157346A (ko) 세포외 소포체를 로딩하는 방법
KR20130048240A (ko) Ｐｃｂｐ―１ 항원에 대한 모노클로날 항체, 및 그의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000